Acurx Pharmaceuticals: Progress and Financial Results for Q2 2026#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CDI_Treatment
Acurx Pharmaceuticals: Progress and Financial Results for Q2 2026
Acurx Pharmaceuticals, Inc. reports significant advancements in developing new antibiotics and provides its financial performance for Q2 2026.
third-news.com
August 14, 2026 at 11:08 AM
Acurx Pharmaceuticals: Progress and Financial Results for Q2 2026#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CDI_Treatment
Acurx Pharmaceuticals Strengthens IP Portfolio with New Patents in Japan and Mexico#Japan#Tokyo#Ibezapolstat#Acurx_Pharmaceuticals#DNA_Polymerase
Acurx Pharmaceuticals Strengthens IP Portfolio with New Patents in Japan and Mexico
Acurx Pharmaceuticals secures new patents in Japan and Mexico for its innovative antibiotic class, further enhancing its position in the biopharmaceutical industry.
third-news.com
August 12, 2026 at 12:16 PM
Acurx Pharmaceuticals Strengthens IP Portfolio with New Patents in Japan and Mexico#Japan#Tokyo#Ibezapolstat#Acurx_Pharmaceuticals#DNA_Polymerase
Acurx Pharmaceuticals Enrolls First Patient in New Clinical Trial for Ibezapolstat to Combat Recurrent C. difficile Infection#United_States#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Enrolls First Patient in New Clinical Trial for Ibezapolstat to Combat Recurrent C. difficile Infection
Acurx Pharmaceuticals has initiated the PATHFINDER clinical trial for its antibiotic Ibezapolstat, aimed at patients suffering from recurrent C. difficile infections.
third-news.com
September 29, 2026 at 12:16 PM
Acurx Pharmaceuticals Enrolls First Patient in New Clinical Trial for Ibezapolstat to Combat Recurrent C. difficile Infection#United_States#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Unveils Groundbreaking Findings at C. difficile Symposium on Novel Antibiotic Ibezapolstat#United_States#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Unveils Groundbreaking Findings at C. difficile Symposium on Novel Antibiotic Ibezapolstat
Acurx Pharmaceuticals showcased the promising in vitro efficacy of their new antibiotic, Ibezapolstat, against C. difficile at a major symposium, highlighting its potential benefits over existing treatments.
third-news.com
September 14, 2026 at 12:12 PM
Acurx Pharmaceuticals Unveils Groundbreaking Findings at C. difficile Symposium on Novel Antibiotic Ibezapolstat#United_States#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Enhances Brand Recognition with FDA and USPTO Approvals for Ibezapolstat#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CIFBEZY
Acurx Pharmaceuticals Enhances Brand Recognition with FDA and USPTO Approvals for Ibezapolstat
Acurx Pharmaceuticals has received FDA conditional acceptance and USPTO trademark allowance for its leading antibiotic candidate, Ibezapolstat, which marks significant progress in its commercialization journey.
third-news.com
August 17, 2026 at 12:07 PM
Acurx Pharmaceuticals Enhances Brand Recognition with FDA and USPTO Approvals for Ibezapolstat#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CIFBEZY
Acurx Forms New Partnership to Enhance Development of Antibiotic Treatment Against Drug-Resistant Infections#United_States#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development#DNA_Polymerase_IIIC
Acurx Forms New Partnership to Enhance Development of Antibiotic Treatment Against Drug-Resistant Infections
Acurx Pharmaceuticals collaborates with Leiden University Medical Center to create innovative DNA Polymerase IIIC inhibitor antibiotics, targeting MRSA infections.
third-news.com
August 10, 2026 at 12:13 PM
Acurx Forms New Partnership to Enhance Development of Antibiotic Treatment Against Drug-Resistant Infections#United_States#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development#DNA_Polymerase_IIIC
Acurx Pharmaceuticals Receives FDA Guidance for Ibezapolstat's Phase 3 Development Program#United_States#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Receives FDA Guidance for Ibezapolstat's Phase 3 Development Program
Acurx Pharmaceuticals has received FDA guidance for its Ibezapolstat program, paving the way for a streamlined Phase 3 trial aimed at treating C. difficile infections.
third-news.com
August 3, 2026 at 12:08 PM
Acurx Pharmaceuticals Receives FDA Guidance for Ibezapolstat's Phase 3 Development Program#United_States#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Unveils New Data on Ibezapolstat for C. difficile Infection Management#USA#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Unveils New Data on Ibezapolstat for C. difficile Infection Management
Acurx Pharmaceuticals presented data highlighting the microbiome preservation potential of Ibezapolstat in treating multiply-recurrent C. difficile infections.
third-news.com
July 14, 2026 at 12:32 PM
Acurx Pharmaceuticals Unveils New Data on Ibezapolstat for C. difficile Infection Management#USA#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Reveals DNA pol IIIC Inhibitors Results at LED3 Conference#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#DNA_pol_IIIC
Acurx Pharmaceuticals Reveals DNA pol IIIC Inhibitors Results at LED3 Conference
Acurx Pharmaceuticals has showcased promising results from its DNA pol IIIC inhibitors at the LED3 Conference, demonstrating advances in antimicrobial treatments.
third-news.com
June 16, 2026 at 12:20 PM
Acurx Pharmaceuticals Reveals DNA pol IIIC Inhibitors Results at LED3 Conference#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#DNA_pol_IIIC
Acurx Pharmaceuticals Announces Promising Q1 2026 Financial and Development Updates#USA#biopharmaceuticals#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Announces Promising Q1 2026 Financial and Development Updates
Acurx Pharmaceuticals reveals strong financial results and groundbreaking advancements in antibiotic development for difficult infections during Q1 2026.
third-news.com
May 13, 2026 at 8:28 AM
Acurx Pharmaceuticals Announces Promising Q1 2026 Financial and Development Updates#USA#biopharmaceuticals#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals
Acurx's Novel DNA Pol IIIC Inhibitors Show Promise for Antibiotic Development#United_States#Staten_Island#Acurx_Pharmaceuticals#Gut_Microbiome#DNA_pol_IIIC
Acurx's Novel DNA Pol IIIC Inhibitors Show Promise for Antibiotic Development
Acurx Pharmaceuticals reveals groundbreaking findings on DNA pol IIIC inhibitors, showcasing their potential in antibacterial therapy while preserving gut microbiome health.
third-news.com
May 4, 2026 at 12:12 PM
Acurx's Novel DNA Pol IIIC Inhibitors Show Promise for Antibiotic Development#United_States#Staten_Island#Acurx_Pharmaceuticals#Gut_Microbiome#DNA_pol_IIIC
Acurx Pharmaceuticals Secures $7.1 Million Through Direct Stock Offering#United_States#stock_offering#Staten_Island#Acurx_Pharmaceuticals#Antibiotics
Acurx Pharmaceuticals Secures $7.1 Million Through Direct Stock Offering
Acurx Pharmaceuticals announces a significant registered direct offering valued at up to $7.1 million aimed at accelerating its antibiotic development.
third-news.com
April 16, 2026 at 12:23 PM
Acurx Pharmaceuticals Secures $7.1 Million Through Direct Stock Offering#United_States#stock_offering#Staten_Island#Acurx_Pharmaceuticals#Antibiotics
Acurx Pharmaceuticals Secures New Patent for Innovative DNA Polymerase IIIC Inhibitors#United_States#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development#DNA_Polymerase_IIIC
Acurx Pharmaceuticals Secures New Patent for Innovative DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals has been granted a new patent for DNA Polymerase IIIC inhibitors, enhancing its portfolio in antibiotic development and treatment for severe bacterial infections.
third-news.com
March 30, 2026 at 11:10 AM
Acurx Pharmaceuticals Secures New Patent for Innovative DNA Polymerase IIIC Inhibitors#United_States#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development#DNA_Polymerase_IIIC
Acurx Pharmaceuticals Unveils Year-End and Q4 Financial Update with Promising Developments#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotics
Acurx Pharmaceuticals Unveils Year-End and Q4 Financial Update with Promising Developments
Acurx Pharmaceuticals provides a comprehensive update on their financial performance for 2025, including innovative trials, strategic advancements in antibiotic development, and significant operational achievements.
third-news.com
March 13, 2026 at 11:09 AM
Acurx Pharmaceuticals Unveils Year-End and Q4 Financial Update with Promising Developments#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotics
Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CDI_Treatment
Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program
Acurx Pharmaceuticals has unveiled a new clinical trial program for Ibezapolstat targeting recurrent CDI, aiming to transform treatment standards and efficacy.
third-news.com
March 9, 2026 at 12:14 PM
Breakthrough in CDI Treatment: Acurx Launches Innovative Ibezapolstat Trial Program#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#CDI_Treatment
Acurx Pharmaceuticals Secures New Patent for Innovative Antibiotic Technology#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#DNA_Polymerase_IIIC
Acurx Pharmaceuticals Secures New Patent for Innovative Antibiotic Technology
Acurx Pharmaceuticals has been awarded a new patent for its cutting-edge DNA Polymerase IIIC inhibitors, strengthening its IP in antibiotic development.
third-news.com
February 2, 2026 at 1:32 PM
Acurx Pharmaceuticals Secures New Patent for Innovative Antibiotic Technology#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#DNA_Polymerase_IIIC
Acurx Pharmaceuticals Shows Progress in Antibiotic Development in Q3 2025 Results#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotics
Acurx Pharmaceuticals Shows Progress in Antibiotic Development in Q3 2025 Results
Acurx Pharmaceuticals unveiled their third-quarter results, highlighting advancements in antibiotic development and patent approvals, while addressing financials.
third-news.com
November 12, 2025 at 12:14 PM
Acurx Pharmaceuticals Shows Progress in Antibiotic Development in Q3 2025 Results#United_States#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotics
Acurx's DNA pol IIIC Inhibitor Shows Promising Gut Microbiome Selectivity at IDWeek 2025#USA#Atlanta#Ibezapolstat#Acurx_Pharmaceuticals#DNA_pol_IIIC
Acurx's DNA pol IIIC Inhibitor Shows Promising Gut Microbiome Selectivity at IDWeek 2025
Acurx provided groundbreaking findings on its DNA pol IIIC inhibitor, ibezapolstat, which shows selective antibacterial properties, at IDWeek 2025.
third-news.com
October 28, 2025 at 12:21 PM
Acurx's DNA pol IIIC Inhibitor Shows Promising Gut Microbiome Selectivity at IDWeek 2025#USA#Atlanta#Ibezapolstat#Acurx_Pharmaceuticals#DNA_pol_IIIC
Acurx Pharmaceuticals Secures New Patent in Australia for Groundbreaking Antibiotic Technology#Australia#Staten_Island#Acurx_Pharmaceuticals#DNA_Polymerase#antibiotic_research
Acurx Pharmaceuticals Secures New Patent in Australia for Groundbreaking Antibiotic Technology
Acurx Pharmaceuticals announces a new patent granted in Australia for DNA Polymerase IIIC inhibitors, enhancing its antibiotic R&D efforts.
third-news.com
October 9, 2025 at 11:41 AM
Acurx Pharmaceuticals Secures New Patent in Australia for Groundbreaking Antibiotic Technology#Australia#Staten_Island#Acurx_Pharmaceuticals#DNA_Polymerase#antibiotic_research
Acurx Pharmaceuticals Receives EMA Approval for Pediatric Use of Ibezapolstat Against C. difficile#United_States#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Receives EMA Approval for Pediatric Use of Ibezapolstat Against C. difficile
Acurx Pharmaceuticals has received a positive opinion from the EMA for its Pediatric Investigation Plan for ibezapolstat, a critical treatment for C. difficile infections in children.
third-news.com
September 30, 2025 at 11:44 AM
Acurx Pharmaceuticals Receives EMA Approval for Pediatric Use of Ibezapolstat Against C. difficile#United_States#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Implements Reverse Stock Split to Boost Share Value#USA#Shareholders#Stock_Split#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Implements Reverse Stock Split to Boost Share Value
Acurx Pharmaceuticals has announced a 1-for-20 reverse stock split, effective August 5, 2025, to enhance its stock value and maintain Nasdaq compliance.
third-news.com
July 31, 2025 at 2:22 PM
Acurx Pharmaceuticals Implements Reverse Stock Split to Boost Share Value#USA#Shareholders#Stock_Split#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Secures $2.67 Million by Exercising Warrants#United_States#biopharmaceuticals#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Secures $2.67 Million by Exercising Warrants
Acurx Pharmaceuticals has announced a successful warrant inducement agreement, generating $2.67 million in proceeds in a bid to bolster its antibiotic development efforts.
third-news.com
June 18, 2025 at 2:17 AM
Acurx Pharmaceuticals Secures $2.67 Million by Exercising Warrants#United_States#biopharmaceuticals#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals
Acurx's Ibezapolstat Shows Promising Results in Latest Clinical Trial for C. Difficile Infection Treatment#USA#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx's Ibezapolstat Shows Promising Results in Latest Clinical Trial for C. Difficile Infection Treatment
Acurx Pharmaceuticals announces positive findings for Ibezapolstat, its innovative antibiotic for treating C. difficile infection, from a Phase 2b clinical trial. This promising data underlines the drug's potential.
third-news.com
June 17, 2025 at 11:15 AM
Acurx's Ibezapolstat Shows Promising Results in Latest Clinical Trial for C. Difficile Infection Treatment#USA#Ibezapolstat#C._difficile#Staten_Island#Acurx_Pharmaceuticals
Acurx Pharmaceuticals Highlights Advancements in Antibiotic Research at Key Scientific Conference#United_States#New_York#Ibezapolstat#Acurx_Pharmaceuticals#DNA_pol_IIIC
Acurx Pharmaceuticals Highlights Advancements in Antibiotic Research at Key Scientific Conference
Acurx Pharmaceuticals showcased significant findings from its research on novel antibiotics at a leading scientific conference, advancing the fight against persistent infections.
third-news.com
June 9, 2025 at 11:44 AM
Acurx Pharmaceuticals Highlights Advancements in Antibiotic Research at Key Scientific Conference#United_States#New_York#Ibezapolstat#Acurx_Pharmaceuticals#DNA_pol_IIIC
Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates#USA#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development
Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates
Acurx Pharmaceuticals delivers an encouraging financial report for Q1 2025, highlighting advancements in antibiotic development and strategic partnerships.
third-news.com
May 13, 2025 at 11:06 AM
Acurx Pharmaceuticals Reports Strong Q1 2025 Results and Key Business Updates#USA#Ibezapolstat#Staten_Island#Acurx_Pharmaceuticals#Antibiotic_Development